# SCN4A

## Overview
The SCN4A gene encodes the alpha subunit of the voltage-gated sodium channel NaV1.4, which is a critical component in the function of skeletal muscle cells. This transmembrane protein is responsible for the rapid influx of sodium ions during the depolarization phase of action potentials, facilitating muscle contraction and neuromuscular activity (George1992Primary). The NaV1.4 channel is composed of four homologous domains, each with six transmembrane segments, and is primarily expressed in adult human skeletal muscle (George1992Primary; Maggi2020Clinical). Mutations in SCN4A can lead to various neuromuscular disorders, highlighting its clinical significance in conditions such as myotonia and periodic paralysis (Cannon2015Channelopathies). The gene's product interacts with other proteins, such as the syntrophin/dystrophin complex, to modulate its function and stability in the muscle cell membrane (SavioGalimberti2012VoltageGated).

## Structure
The SCN4A gene encodes the alpha subunit of the voltage-gated sodium channel NaV1.4, which is essential for muscle function. The protein is composed of four homologous domains (I-IV), each containing six transmembrane segments (S1-S6) (Maggi2020Clinical; George2005Inherited). These domains form a central pore, with segments S5 and S6 lining its wall, while the S4 segment acts as the voltage sensor due to its positively charged amino acids (Maggi2020Clinical). The P loop between S5 and S6 forms the extracellular domain responsible for ion selectivity (Maggi2020Clinical).

The tertiary structure involves the folding of these domains into a three-dimensional shape, crucial for the channel's function. The quaternary structure includes the assembly of the alpha subunit with beta subunits, which modulate the kinetics and voltage dependence of channel activation and inactivation (Catterall2012Voltage‐gated). 

Mutations in SCN4A can affect the channel's function, leading to conditions such as myotonia and periodic paralysis. These mutations often occur in critical regions like the voltage sensor in the S4 segment and the fast-inactivation particle in the III-IV linker (Brenes2021Functional; Maggi2020Clinical).

## Function
The SCN4A gene encodes the alpha subunit of the voltage-gated sodium channel Nav1.4, which is primarily expressed in adult human skeletal muscle. This channel is essential for the rapid depolarization phase of action potentials, a critical process for muscle contraction and neuromuscular activity (George1992Primary). The Nav1.4 channel facilitates the flow of sodium ions into muscle cells, triggering depolarization and enabling the propagation of electrical impulses along the muscle fiber surface and into the transverse tubular system (George1992Primary). This process is vital for the initiation and propagation of action potentials in excitable cells, contributing to normal muscle movement and coordination (I.McClatchey1992The).

The SCN4A gene product, hSkM1, is the human homologue of the tetrodotoxin-sensitive sodium channel found in adult rat skeletal muscle, and it is specifically expressed in skeletal muscle tissue, not in the heart, brain, or uterus (George1992Primary). The channel's structure includes four homologous repeat domains, each with six transmembrane segments, which are crucial for its function as a voltage-gated channel (George1992Primary). Proper functioning of the SCN4A-encoded sodium channel is essential for muscle excitability and contraction, underscoring its importance in maintaining normal neuromuscular function (Ulbricht2005Sodium).

## Clinical Significance
Mutations in the SCN4A gene, which encodes the NaV1.4 sodium channel, are linked to several neuromuscular disorders. These include Hyperkalemic Periodic Paralysis (HyperPP), Paramyotonia Congenita (PMC), and Sodium Channel Myotonia (SCM). HyperPP is characterized by episodes of muscle weakness often triggered by elevated potassium levels, with some patients developing permanent proximal weakness (Cannon2015Channelopathies). PMC involves myotonic stiffness that worsens in cold environments, potentially leading to weakness after cooling or exercise (Cannon2015Channelopathies). SCM presents with myotonic stiffness without periodic paralysis, varying from mild to severe forms (Cannon2015Channelopathies).

SCN4A mutations can also cause severe neonatal episodic laryngospasm (SNEL), marked by abrupt upper airway muscle myotonia and respiratory issues, which can be life-threatening (Matthews2020Muscle). Additionally, some cases of hypokalemic periodic paralysis (HypoPP) are attributed to SCN4A mutations, presenting with weakness during hypokalemia (Cannon2015Channelopathies). Rarely, SCN4A mutations can lead to a myasthenic pattern of weakness, characterized by generalized weakness during brief exercise (Cannon2015Channelopathies). These conditions are often dominantly inherited and require genetic testing for accurate diagnosis (Cannon2015Channelopathies).

## Interactions
The SCN4A gene encodes the alpha subunit of the voltage-gated sodium channel NaV1.4, which is primarily expressed in skeletal muscle cells. This channel is involved in muscle contraction and interacts with various proteins that modulate its function. One significant interaction is with the syntrophin/dystrophin complex, where syntrophins bind to the C-termini of NaV1.4, stabilizing the channel in the plasma membrane and reducing its internalization (SavioGalimberti2012VoltageGated).

The interaction of NaV1.4 with the neurotoxin JZTX-V has been studied extensively. JZTX-V binds to NaV1.4, affecting the channel's activation and inactivation potentials. This binding is mediated by specific hydrophobic and positively charged residues on the toxin, which interact with the channel, highlighting the importance of both hydrophobic and electrostatic interactions in this process (Luo2014Molecular).

Additionally, the SCN4A-encoded channel is part of a protein-protein interaction network that includes other voltage-gated sodium channels and is implicated in various channelopathies. These interactions are crucial for understanding the biological processes and pathways associated with SCN4A and its role in disease (Marín2019An).


## References


[1. (Marín2019An) Milagros Marín, Francisco J. Esteban, Hilario Ramírez-Rodrigo, Eduardo Ros, and María José Sáez-Lara. An integrative methodology based on protein-protein interaction networks for identification and functional annotation of disease-relevant genes applied to channelopathies. BMC Bioinformatics, November 2019. URL: http://dx.doi.org/10.1186/s12859-019-3162-1, doi:10.1186/s12859-019-3162-1. This article has 7 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s12859-019-3162-1)

[2. (SavioGalimberti2012VoltageGated) Eleonora Savio-Galimberti, Michael H. Gollob, and Dawood Darbar. Voltage-gated sodium channels: biophysics, pharmacology, and related channelopathies. Frontiers in Pharmacology, 2012. URL: http://dx.doi.org/10.3389/fphar.2012.00124, doi:10.3389/fphar.2012.00124. This article has 83 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fphar.2012.00124)

[3. (I.McClatchey1992The) Andrea I.McClatchey, Carol S.Lin, Jianzhou Wang, Eric P.Hoffman, Cecilia Rojas, and James F.Gusella. The genomic structure of the human skeletal muscle sodium channel gene. Human Molecular Genetics, 1(7):521–527, 1992. URL: http://dx.doi.org/10.1093/hmg/1.7.521, doi:10.1093/hmg/1.7.521. This article has 38 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1093/hmg/1.7.521)

[4. (Cannon2015Channelopathies) Stephen C. Cannon. Channelopathies of skeletal muscle excitability. March 2015. URL: http://dx.doi.org/10.1002/cphy.c140062, doi:10.1002/cphy.c140062. This article has 165 citations and is from a peer-reviewed journal.](https://doi.org/10.1002/cphy.c140062)

[5. (Maggi2020Clinical) Lorenzo Maggi, Raffaella Brugnoni, Eleonora Canioni, Paola Tonin, Veronica Saletti, Patrizia Sola, Stefano Cotti Piccinelli, Lara Colleoni, Paola Ferrigno, Antonella Pini, Riccardo Masson, Fiore Manganelli, Daniele Lietti, Liliana Vercelli, Giulia Ricci, Claudio Bruno, Giorgio Tasca, Antonio Pizzuti, Alessandro Padovani, Carlo Fusco, Elena Pegoraro, Lucia Ruggiero, Sabrina Ravaglia, Gabriele Siciliano, Lucia Morandi, Raffaele Dubbioso, Tiziana Mongini, Massimiliano Filosto, Irene Tramacere, Renato Mantegazza, and Pia Bernasconi. Clinical and molecular spectrum of myotonia and periodic paralyses associated with mutations in scn4a in a large cohort of italian patients. Frontiers in Neurology, July 2020. URL: http://dx.doi.org/10.3389/fneur.2020.00646, doi:10.3389/fneur.2020.00646. This article has 9 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fneur.2020.00646)

[6. (Matthews2020Muscle) Emma Matthews, Simona Balestrini, Sanjay M Sisodiya, and Michael G Hanna. Muscle and brain sodium channelopathies: genetic causes, clinical phenotypes, and management approaches. The Lancet Child &amp; Adolescent Health, 4(7):536–547, July 2020. URL: http://dx.doi.org/10.1016/s2352-4642(19)30425-0, doi:10.1016/s2352-4642(19)30425-0. This article has 15 citations.](https://doi.org/10.1016/s2352-4642(19)30425-0)

[7. (Catterall2012Voltage‐gated) William A. Catterall. Voltage‐gated sodium channels at 60: structure, function and pathophysiology. The Journal of Physiology, 590(11):2577–2589, April 2012. URL: http://dx.doi.org/10.1113/jphysiol.2011.224204, doi:10.1113/jphysiol.2011.224204. This article has 542 citations.](https://doi.org/10.1113/jphysiol.2011.224204)

[8. (Brenes2021Functional) Oscar Brenes, Raffaella Barbieri, Melissa Vásquez, Rebeca Vindas-Smith, Jeffrey Roig, Adarli Romero, Gerardo del Valle, Luis Bermúdez-Guzmán, Sara Bertelli, Michael Pusch, and Fernando Morales. Functional and structural characterization of clc-1 and nav1.4 channels resulting from clcn1 and scn4a mutations identified alone and coexisting in myotonic patients. Cells, 10(2):374, February 2021. URL: http://dx.doi.org/10.3390/cells10020374, doi:10.3390/cells10020374. This article has 2 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/cells10020374)

[9. (Luo2014Molecular) Ji Luo, Yiya Zhang, Mengting Gong, Shanshan Lu, Yifeng Ma, Xiongzhi Zeng, and Songping Liang. Molecular surface of jztx-v (β-theraphotoxin-cj2a) interacting with voltage-gated sodium channel subtype nav1.4. Toxins, 6(7):2177–2193, July 2014. URL: http://dx.doi.org/10.3390/toxins6072177, doi:10.3390/toxins6072177. This article has 11 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/toxins6072177)

[10. (Ulbricht2005Sodium) Werner Ulbricht. Sodium channel inactivation: molecular determinants and modulation. Physiological Reviews, 85(4):1271–1301, October 2005. URL: http://dx.doi.org/10.1152/physrev.00024.2004, doi:10.1152/physrev.00024.2004. This article has 240 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1152/physrev.00024.2004)

[11. (George2005Inherited) A. L. George. Inherited disorders of voltage-gated sodium channels. Journal of Clinical Investigation, 115(8):1990–1999, August 2005. URL: http://dx.doi.org/10.1172/jci25505, doi:10.1172/jci25505. This article has 297 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1172/jci25505)

[12. (George1992Primary) Alfred L. George, Jeffrey Komisarof, Roland G. Kallen, and Robert L. Barchi. Primary structure of the adult human skeletal muscle voltage‐dependent sodium channel. Annals of Neurology, 31(2):131–137, February 1992. URL: http://dx.doi.org/10.1002/ana.410310203, doi:10.1002/ana.410310203. This article has 129 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1002/ana.410310203)